• LAST PRICE
    127.4800
  • TODAY'S CHANGE (%)
    Trending Up1.1900 (0.9423%)
  • Bid / Lots
    126.8500/ 1
  • Ask / Lots
    128.1200/ 1
  • Open / Previous Close
    127.1100 / 126.2900
  • Day Range
    Low 125.8100
    High 127.5550
  • 52 Week Range
    Low 59.2200
    High 136.6050
  • Volume
    234,464
    below average

Search Criteria

Filter search criteria using below inputs

Click on magnifying glass icon to search

Search Criteria - - - Stocks (0)
CompanyCountrySymbol
Select an index
Price Comparison Graph. See accessible table below
1 Day Comparison Chart Accessibility Table. Wednesday's close: 126.29
TimeVolumeGKOS
09:32 ET2006127.145
09:36 ET100126.14
09:38 ET5400126.51
09:39 ET400126.51
09:41 ET100126.325
09:48 ET200126.31
09:50 ET100125.88
09:59 ET200125.88
10:01 ET1600126.485
10:03 ET824126.135
10:06 ET1066125.95
10:08 ET10860125.9
10:15 ET1400126.25
10:19 ET100126.24
10:24 ET100126.16
10:26 ET200125.9
10:28 ET200125.82
10:30 ET200125.995
10:32 ET323126.025
10:33 ET200126.025
10:35 ET400126.085
10:37 ET702126.18
10:39 ET400126.56
10:44 ET200126.58
10:46 ET123126.715
10:48 ET205126.74
10:50 ET400126.85
10:53 ET5459126.75
10:55 ET511126.73
10:57 ET4901126.45
11:00 ET2746126.7
11:02 ET400126.455
11:04 ET1266126.335
11:08 ET500126.52
11:09 ET200126.74
11:15 ET440126.4781
11:20 ET100126.7
11:26 ET100126.57
11:27 ET100126.645
11:29 ET672126.74
11:31 ET100126.63
11:33 ET600126.87
11:36 ET200126.87
11:40 ET100126.82
11:42 ET300127.03
11:44 ET1633126.94
11:47 ET200127.16
11:49 ET100127.08
11:51 ET108126.99
11:56 ET100127.09
11:58 ET242127.17
12:02 ET209127.11
12:03 ET100127.075
12:05 ET300126.99
12:07 ET250127.01
12:09 ET500127.1
12:12 ET200127.1
12:14 ET200127.08
12:18 ET300127.17
12:21 ET300127.31
12:23 ET406127.2
12:25 ET100127.09
12:32 ET100126.945
12:34 ET100127
12:41 ET300126.9
12:43 ET1701127.08
12:48 ET500127.305
12:56 ET100127.32
12:57 ET100127.31
12:59 ET100127.24
01:01 ET200127.19
01:03 ET300127.29
01:08 ET100127.31
01:10 ET100127.225
01:14 ET100127.08
01:17 ET100126.945
01:19 ET100126.94
01:21 ET800126.78
01:28 ET497126.68
01:30 ET2210126.81
01:35 ET200126.885
01:46 ET100126.71
01:51 ET100126.66
01:57 ET807126.78
02:02 ET100126.79
02:11 ET100126.85
02:13 ET402126.85
02:15 ET100126.87
02:18 ET100126.88
02:20 ET100126.895
02:26 ET100126.895
02:31 ET700126.88
02:33 ET315126.74
02:36 ET535126.63
02:38 ET100126.57
02:42 ET300126.76
02:44 ET446126.89
02:51 ET901126.88
02:54 ET200126.93
03:00 ET922127.05
03:02 ET438126.84
03:09 ET300126.99
03:12 ET202127.3
03:16 ET100127.25
03:18 ET100127.195
03:20 ET450127.265
03:21 ET100127.2
03:23 ET100127.23
03:25 ET2300127.21
03:27 ET1000127.1
03:30 ET200127.12
03:32 ET234127.03
03:34 ET1248126.98
03:36 ET2037126.93
03:39 ET1800127.145
03:41 ET411127.09
03:45 ET932127.04
03:48 ET475127.15
03:50 ET265127.07
03:52 ET598127.085
03:54 ET1513127.22
03:56 ET3085127.455
03:57 ET414127.45
03:59 ET57688127.48
Data delayed at least 15 minutes.
0 New Today
Industry Peers Overview Table
Company sortableMarket Cap sortableP/E Ratio (TTM) sortableEPS Growth (5yr) sortable
United StatesGKOS
Glaukos Corp
6.9B
-39.9x
---
United StatesINSP
Inspire Medical Systems Inc
6.2B
1,070.2x
---
United StatesPEN
Penumbra Inc
7.3B
561.1x
+65.82%
United StatesSTVN
Stevanato Group SpA
6.2B
40.6x
---
United StatesRGEN
Repligen Corp
7.8B
-3,537.1x
+15.08%
United StatesLNTH
Lantheus Holdings Inc
7.5B
17.1x
+35.30%
As of 2024-09-26

Company Information

Glaukos Corporation is an ophthalmic pharmaceutical and medical technology company. It develops novel, dropless therapies and commercializing associated products for the treatment of glaucoma, corneal disorders and retinal disease. Its product candidates include Micro-Invasive Glaucoma Surgery products that involve the insertion of a micro-scale device designed to reduce intraocular pressure (IOP) by restoring the natural aqueous humor outflow pathways for patients suffering from glaucoma and procedural pharmaceuticals based on an intracameral drug delivery technology designed to reduce IOP by delivering therapeutic levels of glaucoma medication from inside the eye over an extended period of time. Its products include transdermal pharmaceuticals that are applied to the eyelid and designed to treat glaucoma, dry eye, presbyopia and other ocular surface diseases and disorders and micro-invasive, bio-erodible sustained release drug delivery implants to improve the vision of patients.

Contact Information

Headquarters
1 GLAUKOS WAYALISO VIEJO, CA, United States 92656
Phone
949-367-9600
Fax
949-367-9984

Executives

Chairman of the Board, Chief Executive Officer
Thomas Burns
President, Chief Operating Officer
Joseph Gilliam
Chief Financial Officer, Senior Vice President
Alex Thurman
Chief Development Officer
Tomas Navratil
Lead Independent Director
Mark Foley

Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.

Open a New Account, or Login if you're a client.

You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.

Open a New Account, or Login if you're a client.

Fundamentals Table
Market Cap
$6.9B
Revenue (TTM)
$341.7M
Shares Outstanding
55.0M
Glaukos Corp does not pay a dividend.
Beta
1.03
EPS
$-3.20
Book Value
$9.40
P/E Ratio
-39.9x
Price/Sales (TTM)
20.3
Price/Cash Flow (TTM)
---
Operating Margin
-39.70%
*GAAP = prior to non-GAAP analyst adjusted earnings.

Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.

Open a New Account, or Login if you're a client.